07:19 AM EST, 01/03/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Friday that it acquired Galzin, an FDA-approved treatment for Wilson Disease.
The company plans to begin US commercialization in Q1 2025 and offer personalized support through its Eton Cares program, including a $0 co-pay for eligible patients.
Additionally, Eton said it acquired European rights to the product, which will continue to be marketed in Europe under the name Wilzin by a third-party distributor.